Ecologic® PANDA formulation inside

Figure 1: Section view of the bowel
Figure 1: Ecologic® PANDA is a multispecies probiotic able to modulate the gut microbiota and hereby improve the intestinal barrier function (level 2) and stimulate the development of the immune system (level 3) to prevent eczema development. 

Ecologic® PANDA is a multispecies probiotic specifically developed to prevent the development of eczema. Ecologic® PANDA has been developed and researched in close collaboration with the Wilhelmina Children’s Hospital of the University Medical Centre of Utrecht. The strains have been selected based on their capacity to modulate the intestinal microbiota in such a way that the immune system reacts to allergens with a relatively mild response (figure 1). 1 2

 

The selected strain combination from the Ecologic® Barrier formulation:

  • Bifidobacterium bifidum  W23
  • Bifidobacterium lactis      W52
  • Lactococcus lactis           W58

Probiotic formulation for reduce of the risk of eczema

In Western societies, the prevalence of allergy is rising and is expected to grow even further (see figure 2). The World Allergy Organisation (WAO) reported that nowadays allergy affects more than 20% of the populations of most developed countries1. The major allergic diseases eczema, asthma, hay fever and food allergy affect not only quality of life but also have an impact on the socio-economic welfare of society. This requests a preventive strategy to overcome these effects.3

An important role for the increase of allergies over de past decades is, according to the hygiene hypothesis, a decreased exposure to microbes early in life.4 This hypothesis is based on the generally accepted fact that establishing a healthy intestinal microbiota early in life contributes to proper intestinal development and maturation of the immune system.5

This relatively low or inappropriate microbial exposure could be a problem for the child’s developing immune system and as such be responsible for the increasing prevalence of allergic diseases. Research has shown that the intestine of babies suffering from eczema shows a less diverse microbiota composition compared to the intestine of healthy babies.6

A potential approach to influence the neonatal development of microbiota and immune system is early administration of specifically selected probiotic strains.

Figure 2: increase in the prevalence of allergic diseases
Figure 2: The past decades have shown an enormous increase in the prevalence of allergic diseases in Western societies.

Clinical support

Ecologic® PANDA has been tested in a randomized double-blind placebo-controlled trial including 102 pregnant women who were at high risk of getting an allergic baby due to a positive family history. Subjects received either Ecologic® PANDA or a placebo which was administered prenatally (in the diet during pregnancy 6-8 weeks prior to delivery) and post.natally (during the first 12 months of life to the child). Results substantiated previous research outcomes by showing that babies which did not develop eczema had a higher microbial diversity (figure 3). Clinical results also showed a significant reduction of eczema after 3 months in the babies receiving Ecologic® PANDA, and a sustainment of this effect until two years after birth7 (figure 4). All phases of the research that led to this product have been published in a PhD thesis. 8

Figure 3: the diversity of the micobial community
Figure 3: Ecologic® PANDA increased the diversity of the micobial community
Figure 4:
Figure 4: Ecologic® PANDA shows a significant reduction of eczema development.

 

Ecologic® PANDA publicaties

 

  • Niers L.E. et al. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. Clin Exp Allergy. 2005;35(11):1481-1489.
  • Niers L.E. et al. Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells. Clin Exp Immunol. 2007;149(2):344-352.
  • Niers L.E. et al. The effects of selected probiotic strains on the development of eczema (the PandA study). Allergy. 2009;64(9):1349-1358.
  • Niers L.E. Probiotic bacteria for prevention of atopic disease. Design and application. PhD thesis. November 2009.

Safety insurance

The use of oral probiotics has been well researched in many different (incl. vulnerable) patient populations, including infants, elderly people and immunocompromised patients. The general conclusion is that there are no safety risks for the studied bacterial strains in the dosages that were used in the studies. Caution is recommended in a number of highly vulnerable patient populations, such as oncology patients with severe leukopenia or mucositis. Probiotics use in acute pancreatitis is contraindicated. Read More about Safety…
 

World Wide availability

The research formulations of Ecologic® are not sold as consumer products. However our worldwide business partners offer a selection of the formulations their own branded product(s). Thus the specific bacterial compositions can be found in different products around the world.

References

  • 1. Niers L.E. et al. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. Clin Exp Allergy. 2005;35(11):1481-1489.
  • 2. Niers L.E. et al. Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells. Clin Exp Immunol. 2007;149(2):344-352.
  • 3. WAO White Book on Allergy, 2011
  • 4. Holgate S.T. et al. Improving the management of atopic disease. Arch Dis Child. 2005;90:826-831.
  • 5. Palmer C. et al. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5(7):e117.
  • 6. Bjorksten B. et al. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol. 2001;108(4):516-520.
  • 7. Niers L.E. et al. The effects of selected probiotic strains on the development of eczema (the PandA study). Allergy. 2009;64(9):1349-1358.
  • 8. Niers L.E. Probiotic bacteria for prevention of atopic disease. Design and application. Proefschrift. November 2009.

Formulation ingredients

Bacterial strains

  • Bifidobacterium bifidum W23
  • Bifidobacterium lactis W52
  • Lactococcus lactis W58

Usage

Dosage Dosage used in studies: 3 grams a day
Dissolve in luke water or dairy